Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Kaposi's sarcoma (KS) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Features include always present findings: Recurrent herpes; and very common findings: Hypermelanotic macule, Abnormality of the lower limb, Neoplasm of the skin, and Macule. 26 total HPO annotations.

Organ System	Phenotype Count	Example Features
Skin	6	Neoplasm of the skin, Papule, Skin nodule
Digestive system	4	Spleen abnormalities (abnormality of the spleen), Abnormality of the gastrointestinal tract, Abnormality of the liver
Brain and nerves	2	Encephalopathy, Fatigue
Blood and immune system	2	Immunodeficiency, Lymphoproliferative disorder
Arms and legs	1	Abnormality of the lower limb
Eyes	1	Abnormal retinal morphology
Growth and development	1	Weight loss
Metabolism	1	Fever
Lungs and breathing	1	Abnormal lung morphology

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for Kaposi's sarcoma, including POMALIDOMIDE (POMALYST, approved 2013). An additional 10 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status
POMALYST	POMALIDOMIDE	—	2013	Available

Orphan Drug Designations

The following drugs have received orphan drug designation from the FDA for Kaposi's sarcoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
alitretinoin	alitretinoin	Galephar Pharmaceutical Research, Inc.	2021	—	Designated
H-Leu-Pro-Pro-Ser-Arg-OH	H-Leu-Pro-Pro-Ser-Arg-OH	Immuno Tech, Inc.	2012	—	Designated
L-glutamyl-L-tryptophan

Gene therapy approaches for Kaposi's sarcoma have been reported in the published literature.

Clinical Trials

32 trials found

Explore Trials

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

32 clinical trials registered, 16 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 1 PHASE3, 11 PHASE2. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06375122](https://clinicaltrials.gov/study/NCT06375122)	Natural History Study of Kaposi Sarcoma	—	National Cancer Institute (NCI)	RECRUITING
[NCT06751355](https://clinicaltrials.gov/study/NCT06751355)	Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial	—	Washington University School of Medicine	RECRUITING
[NCT05859074](https://clinicaltrials.gov/study/NCT05859074)	A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	PHASE1	Memorial Sloan Kettering Cancer Center	RECRUITING
[NCT06638931](https://clinicaltrials.gov/study/NCT06638931)	Agnostic Therapy in Rare Solid Tumors	PHASE2	Instituto do Cancer do Estado de São Paulo	RECRUITING
[NCT04902443](https://clinicaltrials.gov/study/NCT04902443)	Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV	PHASE1	National Cancer Institute (NCI)	RECRUITING

282 publications have been identified in PubMed for Kaposi's sarcoma. Kisho has analyzed 139 by research type. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (30%), and Epidemiology / Natural History (14%).

Research Type	Count	% of Total
Laboratory research	56	40%
Research summaries	42	30%
Disease patterns and progression	20	14%
Patient case studies	8	6%
New treatment approaches	5	4%
Other research	3

Recent Publications

Li X (2026). [PMID: 41885172](https://pubmed.ncbi.nlm.nih.gov/41885172/). *J Cutan Med Surg*. [Case Report / Case Series]
Kildedal DF (2026). [PMID: 41512555](https://pubmed.ncbi.nlm.nih.gov/41512555/). *Biomed Pharmacother*. [Gene Therapy / Novel Therapeutics]
Chakraborty K (2026). [PMID: 41519397](https://pubmed.ncbi.nlm.nih.gov/41519397/). *Prog Biophys Mol Biol*. [Review / Meta-Analysis]
Sun C (2026). [PMID: 41629701](https://pubmed.ncbi.nlm.nih.gov/41629701/). *Nature*. [Basic Science / Preclinical]
Tenny S (2026). [PMID: 28846237](https://pubmed.ncbi.nlm.nih.gov/28846237/). *Unknown Journal*. [Epidemiology / Natural History]
Zhu Q (2026). [PMID: 40574281](https://pubmed.ncbi.nlm.nih.gov/40574281/). *Autophagy*. [Basic Science / Preclinical]
Revenko D (2026). [PMID: 41899609](https://pubmed.ncbi.nlm.nih.gov/41899609/). *Cancers (Basel)*. [Review / Meta-Analysis]
Bhattacharya S (2026). [PMID: 42146703](https://pubmed.ncbi.nlm.nih.gov/42146703/). *bioRxiv*. [Basic Science / Preclinical]
Talla A (2026). [PMID: 41680482](https://pubmed.ncbi.nlm.nih.gov/41680482/). *Nat Med*. [Clinical Trial Publication]
Altunisik Toplu S (2026). [PMID: 41693335](https://pubmed.ncbi.nlm.nih.gov/41693335/). *Cutan Ocul Toxicol*. [Epidemiology / Natural History]

Kisho

Kaposi's sarcoma

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Pyogenic Granuloma-Like Kaposi's Sarcoma.

Kaposi's sarcoma

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Pyogenic Granuloma-Like Kaposi's Sarcoma.